GLP-1RA ‘Might Be Disease-Modifying’ In Knee Osteoarthritis With Type 2 Diabetes
27 Jul 2023 • Glucagon-like peptide-1 receptor agonists “might be disease-modifying” in patients with knee osteoarthritis and type 2 diabetes if treatment is sustained for a sufficient period, according to data. The researchers, who published their findings in the Annals of the Rheumatic Diseases, added that the result may be mediated by weight loss.
KEY TAKEAWAYS: -The researchers identified all patients with knee OA and type 2 diabetes mellitus enrolled in the cohort between Jan. 1, 2011, and Jan. 1, 2017
- The analysis included 1,807 patients with knee OA and comorbid type 2 diabetes mellitus.
- According to Zhu and colleagues, patients who received GLP-1RA therapy lost more weight and were less likely to undergo surgery for knee OA
- In addition, there were statistically significant differences in pain scores and cartilage-loss velocity
- Further investigation is needed to determine the therapy’s effects on OA disease process and joint structure.
Source: Healio | Read full story